Pharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma

被引：0
|
作者：
Jamie E. Flerlage
Monika L. Metzger
Jianrong Wu
John C. Panetta
机构：
[1] The University of Tennessee Health Science Center,Department of Oncology, St. Jude Children’s Research Hospital
[2] The University of Tennessee Health Science Center,Department of Biostatistics, St. Jude Children’s Research Hospital
[3] The University of Tennessee Health Science Center,Pharmaceutical Sciences, St. Jude Children’s Research Hospital
来源：
Cancer Chemotherapy and Pharmacology | 2016年 / 78卷
关键词：
Brentuximab vedotin; Pharmacokinetics; Pediatric; Hodgkin lymphoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1217 / 1223
页数：6
相关论文
共 50 条
  • [41] Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan
    Tien, Feng-Ming
    Tsai, Cheng-Hong
    Liu, Jia-Hau
    Lin, Chien-Ting
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2019, 118 (10) : 1466 - 1470
  • [42] Brentuximab vedotin for lymphoma in paediatric patients
    Sureda, Anna
    Domingo-Domenech, Eva
    LANCET HAEMATOLOGY, 2018, 5 (10): : E433 - E434
  • [43] Brentuximab Vedotin for Stage III or IV Hodgkin's Lymphoma
    Crump, Michael
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (16): : 1559 - +
  • [44] Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
    Salihoglu, A.
    Elverdi, T.
    Karadogan, I.
    Paydas, S.
    Ozdemir, E.
    Erdem, G.
    Karadurmus, N.
    Akyol, G.
    Kaynar, L.
    Yegin, Z. A.
    Sucak, G.
    Ozkocaman, V.
    Topcuoglu, P.
    Ozcan, M.
    Birtas, E.
    Goker, H.
    Baslar, Z.
    Ferhanoglu, B.
    ANNALS OF HEMATOLOGY, 2015, 94 (03) : 415 - 420
  • [45] Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
    Siddiqi, Tanya
    Thomas, Sandra H.
    Chen, Robert
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2014, 7 : 79 - 85
  • [46] Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era
    Graf, Solomon A.
    Gopal, Ajay K.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2014, : 151 - 157
  • [47] THE COST-EFFECTIVENESS OF BRENTUXIMAB VEDOTIN IN HODGKIN LYMPHOMA IN SWEDEN
    Engstrom, A.
    VALUE IN HEALTH, 2014, 17 (07) : A639 - A639
  • [48] Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma
    Arora, Anubha
    Bhatt, Vijaya Raj
    Liewer, Susanne
    Armitage, James O.
    Bociek, R. Gregory
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 95 (04) : 361 - 364
  • [49] Novel immunotherapeutic approaches for pediatric classical Hodgkin lymphoma: Nivolumab or brentuximab vedotin with the AVD regimen
    Okeleji, Olayinka
    Gibson, Amber
    Nunez, Cesar
    Garcia, Miriam B.
    Roth, Michael
    Cuglievan, Branko
    McCall, David
    PEDIATRIC BLOOD & CANCER, 2024, 71 (08)
  • [50] Brentuximab vedotin for the treatment of Hodgkin's and non-Hodgkin's lymphoma
    Reagan, Patrick M.
    Friedberg, Jonathan W.
    EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (05): : 609 - 618
12345